CD5 CAR-T cells (pregene)

N/A

Report date: 2023/06/13 14:51:12

Base Information

Drug NameCD5 CAR-T cells (pregene)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell surface glycoprotein CD5 inhibitors
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShenzhen Pregene Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Pregene Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A